A Randomized, Phase 3, Double-Blind, Crossover Comparison of PRC-063 and Lisdexamfetamine in the Driving Performance of Adults With ADHD

Trial Profile

A Randomized, Phase 3, Double-Blind, Crossover Comparison of PRC-063 and Lisdexamfetamine in the Driving Performance of Adults With ADHD

Completed
Phase of Trial: Phase III

Latest Information Update: 24 Jan 2017

At a glance

  • Drugs Methylphenidate (Primary) ; Lisdexamfetamine
  • Indications Attention-deficit hyperactivity disorder
  • Focus Therapeutic Use
  • Sponsors Rhodes Pharmaceuticals
  • Most Recent Events

    • 17 Jan 2017 Status changed from recruiting to completed.
    • 18 Feb 2016 Planned End Date changed from 1 Feb 2016 to 1 Feb 2017, according to ClinicalTrials.gov record.
    • 18 Feb 2016 Planned primary completion date changed from 1 Jan 2016 to 1 Sep 2016, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top